Ren Bingbing, Yang Haitao, Mao Yingying
Department of Pediatric Surgery, General Hospital, Tianjin Medical University, Tianjin, China.
Department of General Practice, Liaocheng People's Hospital, Liaocheng, Shandong, China.
Front Oncol. 2025 May 9;15:1548008. doi: 10.3389/fonc.2025.1548008. eCollection 2025.
Colorectal squamous cell carcinoma (CSCC) is an exceedingly rare malignancy, accounting for approximately 0.41% of all colorectal cancers. This case report describes a 52-year-old male with a history of chronic bronchitis, varicose vein of the lower limb, diabetes, and Hepatitis B cirrhosis, who presented with worsening abdominal pain. The patient underwent a right hemicolectomy, and postoperative pathology revealed a moderately differentiated CSCC with proficient mismatch repair (pMMR) status. The patient was initially treated with the CAPEOX adjuvant chemotherapy regimen, the patient's condition unfortunately progressed. Therefore, the treatment plan has been adjusted to include nab-paclitaxel and carboplatin, in combination with camrelizumab, an Anti-PD-1 therapy, for antitumor therapy. The combination therapy resulted in a partial response. This case highlights the potential efficacy of Anti-PD-1 therapy combined with chemotherapy in CSCC, suggesting a possible treatment approach for this rare cancer subtype.
结直肠鳞状细胞癌（CSCC）是一种极为罕见的恶性肿瘤，约占所有结直肠癌的0.41%。本病例报告描述了一名52岁男性，有慢性支气管炎、下肢静脉曲张、糖尿病和乙型肝炎肝硬化病史，因腹痛加重就诊。患者接受了右半结肠切除术，术后病理显示为中度分化的CSCC，错配修复功能正常（pMMR）。患者最初接受CAPEOX辅助化疗方案治疗，但不幸的是病情进展。因此，治疗方案调整为包括纳武利尤单抗和卡铂，联合抗程序性死亡蛋白1（PD-1）疗法卡瑞利珠单抗进行抗肿瘤治疗。联合治疗产生了部分缓解。本病例突出了抗PD-1疗法联合化疗在CSCC中的潜在疗效，为这种罕见的癌症亚型提示了一种可能的治疗方法。
